Macro Economic Group - In December, M2 growth was 8.5%, exceeding Wind's expectation of 7.9% and up from 8.0% in November. M1 growth was 3.8%, matching expectations but down from 4.9% in November, indicating a slowdown in money velocity [4] - The total social financing (TSF) in December grew by 8.3%, slightly above the expected 8.2% but down from 8.5% in November. The TSF increment was 2.21 trillion yuan, surpassing the expected 1.82 trillion yuan but down from 2.49 trillion yuan year-on-year [4] - Bank credit in December increased by 910 billion yuan, exceeding the expected 679.4 billion yuan and up from 390 billion yuan in the previous month. However, it was down 800 billion yuan year-on-year [5] Industry Comprehensive Group - Siyi Electric (002028.SZ) reported a revenue of 21.2 billion yuan for 2025, a 37.2% year-on-year increase, with Q4 revenue reaching 7.38 billion yuan, up 46.1%. The net profit attributable to shareholders was 3.16 billion yuan, a 54.4% increase, exceeding market expectations [12] - Guanghe Technology (001389.SZ) forecasted a net profit of 980 million to 1.02 billion yuan for 2025, a growth of 45% to 50.8%. The Q4 net profit was estimated at 280 million yuan, a 50.4% increase, driven by strong demand for server PCB boards [13] Advanced Manufacturing Group - The UK AR7 offshore wind auction resulted in 8.4GW of capacity, exceeding expectations and marking a historical high. This sets the stage for significant supply chain orders in the coming years, with a peak delivery expected between 2028 and 2030 [15] - The State Grid has confirmed a total investment of 4 trillion yuan for the 14th Five-Year Plan, a 40% increase from the previous plan, focusing on accelerating ultra-high voltage construction and enhancing supply chain capabilities [16] Consumer Group - The Financial Regulatory Bureau emphasized the need for financial support to boost consumption and investment, particularly in sectors like real estate, healthcare, and small businesses. This is expected to benefit consumer sectors such as automobiles and home appliances [18] - Juzhi Bio's second collagen medical device has been approved, enhancing the focus on the collagen market, which is gaining traction in aesthetic and skin repair applications [19] - Liufeng Group reported a same-store sales growth of 15% for Q4 2025, driven by increased customer flow and product pricing strategies, indicating strong growth momentum [19]

Investment Rating - The report initiates coverage with an OUTPERFORM rating, setting a target price of Rmb 419.80, indicating a potential upside of 25.5% from the current price of Rmb 338.65 [2][9]. Core Insights - Shanxi Jinbo Bio-Pharmaceutical is a leading domestic company in the industrialization of recombinant human collagen, holding three Class III medical device certificates for its products, which positions it favorably in the market [3][11]. - The company reported a revenue of Rmb 1.44 billion in 2024, reflecting a year-on-year growth of 84.92%, driven by significant increases in its medical devices, functional skincare products, and raw materials segments [3][8]. - The report anticipates revenue growth for 2025-2027 to reach Rmb 2.17 billion, Rmb 2.92 billion, and Rmb 3.72 billion, respectively, with growth rates of 55%, 37%, and 29% [9]. Summary by Sections Company Overview - Shanxi Jinbo Bio-Pharmaceutical specializes in recombinant collagen medical devices, with a focus on injectable products that are classified as Class III medical devices, which have stringent approval processes and high technical barriers [3][11]. - The company has established a significant market presence with its proprietary brand Wei Yimei and has also engaged in contract manufacturing for L'Oréal's SkinCeuticals brand [3][27]. Financial Performance - The company has shown consistent revenue and profit growth over the past five years, with a net profit of Rmb 732 million in 2024, up 144% year-on-year [8][9]. - The gross profit margin for 2024 was reported at 92.02%, with the medical device segment achieving a margin of 95.03% [8][9]. Product and Market Position - The medical device segment accounted for 87% of total revenue in 2024, with a compound annual growth rate (CAGR) of 94% from 2020 to 2024 [25][27]. - Jinbo Bio's main products include recombinant collagen injectables, which are primarily used in aesthetic medicine and surgical repair treatments [23][27]. Strategic Partnerships - The company has formed a strategic partnership with Yangshengtang, leveraging its extensive retail network of over 3 million outlets to enhance market penetration and brand visibility [4][20]. - This collaboration is expected to facilitate the application of Jinbo's collagen products across various sectors, including skincare and health products [4][20]. Research and Development - Jinbo Bio is actively investing in R&D, with a focus on its new drug EK1, which is in the pre-clinical stage and aims to address broad-spectrum antiviral needs [5][9]. - The company holds multiple patents for its core ingredients, enhancing its competitive edge in the high-end skincare market [4][20].